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fects on intestinal calcium and phosphate absorption andSecondary hyperparathyroidism (SH) is a universal
bone calcium and phosphate mobilization, calcitriol cancomplication of chronic renal failure. In early renal
induce hypercalcemia and hyperphosphatemia, oftenfailure, alteration in vitamin D metabolism plays a key
precluding its use at therapeutic doses. Therefore, anrole in the development of SH [1–4]. Low levels of
analog of calcitriol that retains the therapeutic effects but1,25(OH)2D3 and decreased repression of the PTH gene
has minor effects on calcium and phosphate metabolismtranscription may allow a greater synthesis and secretion
would be an ideal tool for the treatment of secondaryof PTH. As renal disease progresses, the number of vita-
hyperparathyroidism.min D receptors (VDR) in the parathyroid glands (PTG)
decrease [5–8]; thus, the PTG becomes resistant to the
action of 1,25(OH)2D3. In addition, “uremic toxins” may VITAMIN D ANALOGSfurther decrease the suppressive effect of 1,25(OH)2D3
The biological actions of calcitriol are mediated by a[9]. Concomitantly with the above-described alterations,
nuclear VDR. At present, there is evidence for only a sin-hyperplasia of the PTG develops and a decreased num-
gle form of the VDR. Thus, the same VDR mediatesber of calcium receptors (CaR) [10, 11] further increases
both the calcemic actions and the non-classical poten-the resistance of the PTG to serum ICa. Thus, higher
tially therapeutic actions of calcitriol. The novel aspectserum calcium is necessary to suppress SH. Recently,
of recently developed analogs is their differential actions,investigators examined the clonality of hyperplastic tu-
compared to calcitriol in vivo. In fact, as these analogsmors using X-chromosome inactivation analysis [12]. In
have a relatively high affinity for the vitamin D receptor,about two thirds of uremic patients with refractory S.H.
usually within one order of magnitude, it is not unex-harbored at least one monoclonal parathyroid tumor.
pected that they are able to mimic many of the actionsPhosphate independent of serum Ca and 1,25(OH)2D3
of calcitriol in vivo. The unique feature of therapeuticallyincreases PTH synthesis and secretion by a post-tran-
scriptional mechanism [13–19]. Dietary phosphate also useful analogs is their ability to efficiently support some
regulates parathyroid growth [20]. Low phosphate diet but not all calcitriol associated activities. The potential
increases p21, a repressor of the cell cycle and inhibitor mechanisms through which this selectivity could be
of parathyroid gland hyperplasia, while high phosphate achieved are summarized in Figure 1. Most commonly, the
enhances transforming growth factor alpha (TGF) and analogs display decreased potency in enhancing intestinal
the epidermal growth factor receptor (EGFR) known to absorption or bone mobilization of calcium and phos-
play an important role on cell proliferation. phate. The selectivity is not always cell or tissue specific
The vitamin D hormone, 1,25(OH)2D3 (calcitriol), the but can be gene or process specific within the same tissue.
most active metabolite of vitamin D, controls parathy- The structure-activity relationship for ligand-mediated
roid gland growth and suppresses the synthesis and secre- transcriptional regulation has been studied in detail [25].
tion of parathyroid hormone. Because of its effects on The A-ring structure is most crucial, especially the hy-
PTH suppression, calcitriol has been successfully used droxyl groups, for binding to the VDR. Modification of
in the treatment of secondary hyperparathyroidism that the D-ring or side chain does not greatly affect VDR
almost always accompanies chronic renal failure [21, 22]. binding, but can influence biological potency by altering
The efficacy of intravenous calcitriol in suppressing PTH the pharmacokinetics or catabolism. Analogs can also pro-
in patients with secondary hyperparathyroidism is well duce distinct conformational changes in the VDR that
established [23, 24]. However, because of its potent ef- may produce gene-specific actions. A combination of
structural modifications can produce analogs with di-
verse biological profiles.Key words: vitamin D, hyperparathyroidism, uremia, hypercalcemia,
hyperphosphatemia. Recruitment of coactivators or co-repressors also can
play an important role on vitamin D analogs transcrip- 2002 by the International Society of Nephrology
S-143
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Fig. 1. Potential sites of differential actions
of 1,25(OH)2D3 and its analogs. The possible
steps in the vitamin D activation pathways at
which differences in vitamin D analog action
could lead to selective activities in vivo are
shown. The steps diagrammed include: 1)
DBP affinity, 2) interaction with other serum
proteins including lipoproteins, 3) cellular up-
take, 4) conversing to active metabolites, 5)
catabolic inactivation, 6) activation of the non-
genomic pathway through a membrane vita-
min D receptor (mVDR), 7) interaction with
the nuclear vitamin D receptor (VDR), 8) for-
mation of the VDR-RXR complex, 9) binding
to the activated complex to DNA, and 10)
formation of the preinitiating complex RNA
polymerase II (RNApol) (reproduced from
[40]; used with permission).
Fig. 2. Chemical structure of calcitriol and
several vitamin D analogs.
tion-induced biological actions. Work from Takeyema 22-OXACALCTRIOL (OCT)
et al [26] demonstrated that calcitriol can recruit binding OCT differs from calcitriol only by a substitution of
of several coactivators to the VDR that may enhance the an oxygen in place of carbon 22 in the side chain (Fig. 2).
activation of transcription, whereas 22 oxa-calcitriol re- The affinity of 22-oxacalcitriol for the VDR is about 8
cruits only a subset of these, which could potentially pro- times lower than that calcitriol, consistent with its lower
activity in suppressing PTH. Studies in animals demon-duce biological effects distinct from those of calcitriol.
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Fig. 3. Effects of 1,25(OH)2D3 and 19-nor 1,25(OH)2D2 on plasma
ionized calcium levels in parathyroidectomized rats fed a calcium-defi-
cient diet. Rats were given daily injections of vehicle (white bar),
1,25(OH)2D3, or 19-nor-1,25(OH)2D2 for 9 days.
strated that OCT is rapidly cleared from the circulation;
the short half life may be secondary to diminished affinity
for DBP that is approximately 400–500 times less than Fig. 4. Effects of 1,25(OH)2D3 and 19-nor 1,25(OH)2D2 on intestinal
1,25(OH)2D3 VDR binding in uremic rats. Rats were treated withof calcitriol [27–30]. The low calcemic and phosphatemic
vehicle, 1,25(OH)2D3 (2 or 6 ng), or 19-nor-1,25(OH)2D2 (25 ng or 100effect of OCT may be secondary to low affinity for DBP.
ng) three times a week for 8 weeks. All data are mean  SEM. N 
Currently the mechanism for the differences in the dura- 11 to 15 rats per group. Asterisk and double asterisk indicate P  0.01
an P  0.05 versus uremic  1,25(OH)2D3–6 ng, respectively (repro-tion of the effects in the parathyroid glands versus the
duced from [36]; used with permission).
intestine and bone are not completely understood, but
the findings indicated that stimulation of intestinal cal-
cium absorption and bone resorption are short-lived re-
19-NOR 1,25(OH)2D2 (19-NOR)sponses that require continuous exposure to vitamin D
compounds. On the other hand, even a short exposure This vitamin analog lacks the exocyclic carbon 19 and
of the parathyroid gland to OCT leads to a prolonged has a vitamin D2 side chain (double bone in carbon 22
suppression of PTH. The mechanism of PTH suppression and extra carbon in 28 position) (Fig. 2). We demon-
strated that 19-nor 1,25(OH)2D2 suppress parathyroidby OCT was similar to that of calcitriol in that the analog
hormone secretion in primary cultures of bovine parathy-decreased PTH mRNA, suggesting that it was also acting
roid cells as potently as calcitriol [34]. In addition, thisat the level of gene transcription [31]. Studies in animal
compound can suppress pre-pro PTH messenger RNAmodels with experimental renal failure demonstrated
and PTH secretion without inducing hypercalcemia orthat OCT was able to suppress PTH over a wide dose
hyperphosphatemia.range with no change in serum calcium. In contrast, doses
Daily administration of 19-nor 1,25(OH)2D2 to para-of calcitriol just above those that suppress PTH produced
thyroidectomized rats fed either a calcium or a phospho-a significant increase in serum calcium. The effect of
rus-deficient diet for 9 days produced smaller increases
OCT on renal osteodystrophy was examined by Monier-
in plasma calcium and phosphate than calcitriol. Dose-
Faugere et al [32] in dogs made uremic by subtotal ne- response studies demonstrated that 19-nor 1,25(OH)2D2phrectomy. OCT significantly decreased PTH levels. The is approximately 10 times less active than calcitriol in
analog reversed abnormalities in bone formation, includ- mobilizing calcium and phosphate from bone (Fig. 3) [35].
ing woven osteoid and fibrosis. However, no change in Moreover, in contrast to calcitriol, which up regulates
the rate of bone turnover was observed. While hypercal- the VDR in the intestine, 19-nor-1,25(OH)2D2 has the
cemic episodes occurred, OCT did not induce low turn- opposite effect [36] (Fig. 4).
over bone disease. OCT significantly reduced bone mar- The efficacy of 19-nor 1,25(OH)2D2 in renal failure
row fibrosis and decreased markers of bone turnover in patients was demonstrated in a recent study [37] in 78
patients. Placebo was given to approximately one thirdpatients with end stage renal failure [33].
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Fig. 5. Changes in the levels of intact PTH ex-
pressed as a percentage of change from base-
line values during the study period in placebo-
treated (open circle) and paricalcitriol-treated
(closed circle) groups. The bars depict the
doses of paricalcitriol that increase according
to protocol. (Reproduced from [37]; used with
permission).
Fig. 6. The values for normalized serum cal-
cium (upper lines) and serum phosphorus (lower
lines) during the 12 weeks of study in placebo
(open circle) and paricalcitriol (closed circle)
groups. * P  0.05. (Reproduced from [37];
used with permission).
of the patients and 19-nor 1,25(OH)2D2 was administered cemic activity is much less understood. Early studies with
1(OH)D2 show that it is less toxic than 1(OH)D3 whento the other two-thirds The dose was initially 0.04 g/kg
the compounds were administered chronically [38]. Para-and rose to an average of 0.12 g/kg during the course
doxically, the stimulation of calcium transport and boneof the 7 week study. Serum PTH levels dropped an aver-
mobilization by 1(OH)D2 and 1(OH)D3 were not dif-age of approximately 60% (Fig. 5) with only a slight
ferent [38]. Recently Maung et al [39] reviewed theirincrease in serum calcium, from 9.24  0.12 to 9.5 
experience with 1(OH)D2. The investigators found, in0.15 (Fig. 6).
patients with renal failure, that both oral and intravenous
preparations of 1(OH)D2 were effective in controlling
1(OH)D2 secondary hyperparathyroidism. They also noted smaller
This vitamin D analog is a pro-hormone and must be increments in serum calcium and phosphorus levels with
converted by the liver to 1,25(OH)2D2 before it becomes intravenous administration compared with oral therapy.
However, the prevalence of hypercalcemia and hyper-an active compound (Fig. 2). The basis for the low cal-
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are decreased in parathyroid glands from chronically uremic dogs.phosphatemia still remains high with the IV therapy.
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